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A. Introduction – What is corporate
responsibility?
Corporate responsibility (CR) is becoming
a stronghold on board agendas. While some-
times seen as an instrument for communica-
tion (and hence being duty of the public rela-
tionship departments), companies are increa-
singly perceiving it as a valuable management
tool: it allows for ensuring sustainability inclu-
ding economic and financial sustainability,
managing risk such as reputation at stake and
enhancing relationship to stakeholders (rat-
her than just focusing on relationship to inves-
tors and rather than just establishing one-way
communication to non-investor stakeholders).
Therefore, it is more a management function,
which “at the end of the year” uses its public
relation teams to provide for a consolidated
communication effort, the company’s sustai-
nability report.
Corporate responsibility basically covers three
domains:
Corporate governance primarily focuses on
compliance with (inter)nationally establis-
hed corporate governance codices. This
includes, but is not limited to providing for
anti-fraud and anti-corruption countermea-
sures.
Corporate citizenship, ‘being a good citi-
zen’, is the company’s voluntary commit-
ment to non-profit activities. This part
covers those activities which are usually
perceived under the umbrella of corporate
responsibility and corporate social respon-
sibility, respectively, such as giving dona-
tions and running non-profit foundations
for public research.
Corporate social responsibility (CSR) in its
narrower sense addresses the company’s
responsibility towards the environment
(which focuses on reducing the climate
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impact of the company’s activities), towards
its employees (which focuses on establis-
hing appropriate work safety standards
and avoiding, e.g., forced labor and child
labor) as well as towards its economic sta-
keholders, its investors.
The roots of corporate (social) responsibi-
lity are in the philanthropic domain. Oftenti-
mes, this led to constellations in which the
CR/CSR functions of a company were seen as
a part of public relations; subsequently the
function itself was and is located in PR depart-
ments. It, however, can be used as a very power-
ful instrument for managing reputation risk.
Warren Buffet once said that “it takes 30 years
to build a company’s reputation, but it takes
only 30 minutes to destroy it”. In the times of
fast communication via internet, bad news
and bad rumors spread faster than any public
relations team can react. Doing something
against upfront – reputational risk manage-
ment – will be cheaper and more reliable.
Analogously, ‘access to medicine’ also is
often perceived as being just an instrument
of corporate citizenship. The authors will make
a case for the idea that the benefits of ‘access
to medicine’, however, may go well beyond
‘just giving’. Under certain circumstances,
which are discussed in detail below, there is
a valid business case for companies to enga-
ge here – going even further and beyond repu-
tational risk management towards tangible
economic benefits.
Furthermore, the domains discussed befo-
re are the ones which are in the centre of dis-
cussions surrounding corporate responsibili-
ty. Their nature is a rather defensive one – avoi-
ding non-compliance with regulations and
expectations, avoiding the impression of ego-
centric management, avoiding negative repu-
tation. The authors will make an argument for
leaving the defensive, exculpatory approach
behind and moving towards proactively sha-
ping an economically beneficial surrounding
by using the ‘toolbox’ usually associated with
‘defensive and exculpatory corporate respon-
sibility’.
The rationale for this argument can be made
clear by one example. This example rests on
the assumption that public health is the foun-
dation for economic activity. Countries which
were able to ensure general well-being for all
their citizens are likely to be those countries
which host stable markets. The authors will
discuss below that instable markets may be
one of the root causes for the lack of ‘access to
medicine’ – providing the foundation for public
health may help stabilizing those markets and
thereby opening the door for a successful mar-
ket penetration. This example may even go
further. Beyond ensuring availability of drugs
for ‘neglected diseases’ such an initiative may
prevent instability of a company’s stable home
ground markets as those ‘neglected diseases’
may very well spread into these home mar-
kets and destabilize them.
What is global access?
Before discussing the options for enhan-
cing business models in detail, we want to take
a step back and have a look at what global
access actually means.
The intensity of public scrutiny against
‘Pharma’ and ‘Big Pharma’ in particular is well
known. In those respects, which may be addres-
sed by an ‘access to medicine’ program, there
are several aspects and perceptions leading to
this scrutiny:
One major driver is the conflict of being
dependent on medical care on the one hand
and the enormous profitability of Big Phar-
ma in the past on the other hand. Even in
times before the current financial crisis,
pharmaceutical companies usually were
able to deliver higher shareholder value
than most other industries  (Angell, 2005).
The usually high prices for patented
brand drugs can be considered as a major
driver for this success. On the flipside, howe-
ver, these prices will exceed the financial
capabilities of third world patients up to
parts of first world patients. These poten-
tial but not-served patients form a large
group of ”neglected patients”.
The need to continue and outdo the previo-
us year’s success as well as analysts’
expectations has pharmaceutical compa-
nies rely on premium priced drugs. This in
turn has companies focus on first world
markets. Their economies as a whole as well
as the individuals are more likely to be weal-
thy enough to pay the prices of premium
priced drugs.
In the consequence, other markets are
not served – simply due to the fact that they
will not be able to pay the bill. These mar-
kets are referred to as ”neglected markets”.
The aforementioned optimization rule does
apply on disease areas, too. If markets, who
are not likely / expected to be able to pay
the bill, are facing diseases not prevalent
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in first world countries, there is a very high
likelihood that the pharmaceutical indus-
try in general will disregard  the diseases
and not spend R&D resources on these
disease areas. These comprise the so-called
”neglected diseases”.
Although neglected patients and neglected
markets may not be served, they may play
an important role in the approval process.
In order to obtain drug approvals, large cli-
nical studies have to be performed for drugs
and their indications.
It is common among pharmaceuticals
to outsource these to offshore service pro-
viders in second or third world countries
as first world patients are more and more
resistant to take part in those trials. The
reason for this maybe that they at least
have access to other drugs which target the
same disease (while being maybe less
effective or having more sincere side effects)
or the symptoms.
Public critics point out that patients in
offshore countries bear the risk of untes-
ted drugs while not being able to get those
medicines once they are approved (and
highly priced; one example for these critics
is Shaa, 2006).
The perception of this behavior led to the
triad of ‘neglected patients – neglected disea-
ses – neglected markets’. This in turn trigge-
red various initiatives aiming at making medi-
cine available to those, who need it, but can-
not afford it: ‘access to medicine’ or ‘global
access’.
B. The corporate action plan towards
‘access to medicine’
As mentioned before, ‘access to medicine’
is capable of providing tangibly economic
benefits, beyond its philanthropic value and
reputation risk mitigation. The underlying
principle is the fact that all angles of the triad
actually are markets. This connection is often
depicted as a pyramid (Prahalad, 2004)(Figu-
re 1).
The pharmaceutical industry is perceived
as harvesting the ‘top of the pyramid’ only,
where a small, but wealthy class of patients
resides. Neglected reputation once was the ini-
tial driver of ‘access to medicine’ programs and
has been well discussed in the past. Working
towards the famous ‘bottom of the pyramid’,
however, will allow for unlocking new busi-
ness potential.
Any response to those opportunities, howe-
ver, has to be embedded in the corporate stra-
tegy. Technically speaking, the first step of
each action plan is making global access real-
ly a part of the strategy. The triad itself defi-
nes the set of potential strategy approaches:
‘Neglected patients’: The ‘classical’ respon-
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se is providing drugs for free to particular
countries. The business case for such a pro-
gram usually comes from reducing reputa-
tional risk, firing the imagination of brands
and the firm’s responsibility as well as
replacing marketing expenses in the nar-
rower sense by marginal cost of producti-
on which cannot be recovered. The focus of
business case modeling will be on defining
the appropriate cost of the products given
away for free.
‘Neglected markets’: A business case for
penetrating additional markets – besides
contributing to reputational risk reducti-
on and positive marketing effects – usual-
ly aims at providing a tangible economic
from shifting economic risk towards part-
ners while again ensuring contribution
margin from large volumes and low prices.
The main success factor for the business
case will not be a matter of quantitative
modeling but rather than that finding an
appropriate operating model which achie-
ves the aforementioned goals.
Besides this primary concept, economic
stability may further enhance or provide a
‘brick’ of a neglected markets business
model. Serving a market not served before
will contribute to public health in the
respective country. This may stabilize a mar-
ket which was avoided before due to per-
ceived or actual instability and hence the
initiative may provide the grounds for
‘upgrading’ such a market to a prioritized
emerging market.
‘Neglected diseases’: Programs in this group
focus on researching and developing drugs
that are especially relevant for these mar-
kets due to climate related conditions or
other reasons, and effectively sold at a low
price in those very large markets. Business
cases here focus on providing contributi-
on margin for overhead (incl. R&D) by
increasing volume. If the volume is large
enough, the product of price and volume
less the marginal cost of production may
provide sufficient contribution margin for
recovering the associated R&D cost as well
as associated overhead cost for production
and administration. The rather intangible
benefit of reducing reputational risk as well
as the rather tangible benefit of being able
to replace marketing cost may be achieva-
ble here, too. The key success factor of busi-
ness case modeling will be defining the set
of costs which need to be recovered.
Beyond this primary approach, there
may be a long-term benefit, too. Neglected
diseases are not restricted to third world
markets far away anymore. Globalization
may carry a disease into a first world mar-
ket; climate change may pave the path for
such a disease to advance to first world mar-
kets. Having a drug on the shelf in such a
case will be a competitive advantage.
Based upon the strategic decision which
opportunity to chase, the business case – both
in terms of the operating model and in terms
of the targeted financials – needs to be trans-
lated into an operational plan. Upfront a case
will have to be made for each of those opti-
ons.
In order to make business case modeling
successful two requirements have to be fulfil-
led. At first, the business case needs – despi-
te the intangible effects which significantly
contribute to the benefits – to provide a true
and fair view in order to truly support decisi-
on makers. Secondly, the business case has to
be able to gain the support needed and thus
has to be able to work out the actual benefits.
The strategy approaches stated above and their
benefits will be discussed in detail in the fol-
lowing sections giving particular attention on
how to ensure successful business case mode-
ling. (It shall be noted that the following ana-
lysis of how to establish a business case is focu-
sing on ‘hard’, tangible economic benefits. The
reader should keep in mind that those tangi-
ble benefits usually will be accompanied by
soft factors, such as positive image / brand
effects as well as reduction of reputational
risk.)
C. Business enhancement at the bot-
tom of the pyramid - neglected
patients
Being aware of their responsibility phar-
maceutical companies responded to the chal-
lenge in various ways: Merck Co. brought its
’Medical Outreach Program’ to life which ensu-
res the availability of vaccines, which origi-
nally were developed for first world markets,
in third world countries. The total of relief con-
tributions for this program amounts up to 3.3
billion USD according to the company’s corpo-
rate responsibility report of 2008. The program
reaches a number of 104 countries across three
continents (Merck & Co. Inc., 2007).
Bristol-Myers Squibb’s ’Secure the Future’
program goes a step beyond. The program built
‘fully fledged’ communities for HIV patients
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in Africa, where they do not only receive requi-
red medication (out of Bristol-Myers Squibb’s
brand drug portfolio), but are also given a soci-
al home.
While it might seem that this kind of pro-
gram only triggers cost and negatively impacts
the bottom line, we argue that there is the
benefit of positively impacting the company
in terms of reputation risk. The transmission
mechanism for translating the intangible bene-
fit of reduced risk into a tangible one was
researched and also proven by studies (see,
e.g., Bartram, 2001): a company’s value is deter-
mined by discounting its expected future cash
flow; the discount rate will include a risk pre-
mium, which can and will be reduced by miti-
gating the risk drivers upfront which might
turn into losses in the future. Hence, in the
long run, any risk reduction will positively
impact corporate value.
Beyond its origin the approach, however,
is not restricted to third world patients. Pfi-
zer, for example, runs a similar program (‘Main-
tain’) for U.S. patients in need. Pfizer first set
up a patient-assistance program for as early
as in 2004 (Pfizer, 2007). In the wake of the
financial crisis in 2008/9 Pfizer is extending
this program to those who lost their job and
subsequently their health insurance due to
the financial crisis and thus cannot afford pres-
cription drugs anymore.
It should be noted, however, that Pfizer's
program does not cover all prescription drugs
(Miley and Thomaselli, 2009). Major oncolo-
gy drugs, for example, are not included alt-
hough usually being the ones which are far
more expensive. This issue in combination
with communicating total cost figures based
on list prices once again put those programs
under scrutiny. Thus careful design of the busi-
ness case, which should serve as the platform
for the communication strategy, too, is sug-
gested.
Key success factors for successful business case
modeling
The first hand benefit of such a program
seems to be clear: it is its public relations value.
The cost of such a program deserves a more
thorough look. Pfizer claims the cost of its pre-
ceding program to amount to 4.8 billion USD
(Miley and Thomaselli, 2009). This figure is
based on the list price of the drugs. This
approach, however, may be misleading: The
benefit of such a program can, but should not
be compared to the revenue usually associa-
ted with the products which are now given
away for free, as opportunity costs do not arise.
Production given away for free is not crowding
out production which would be associated
with revenue. Rather than that production
associated with revenue does simply cease as
the market itself has vanished. Thus revenue
at list prices will not occur anyway.
We make an argument for considering mar-
ginal cost of production instead. (For the sake
of completeness, it should be noted that the
argumentation stated above must not conclu-
de that no cost occur as there are no opportu-
nity cost. The actual cost of production does
occur.) These are defined as the change in total
cost that arises when the quantity produced
changes by one unit. This approach, however,
has to answer the question, why the business
case should leave the principles of multi-period
product life cycle costing and neglect major
cost items – research & development and mar-
keting. 
The role of R&D: Any business case for such
a program must be distinguished from a
business case for a product or target disea-
se area. Drugs given away for free should
not be charged with the cost for R&D, as
these customers would never be able to pur-
chase the product and hence would never
be able to contribute to R&D. Hence, consi-
dering R&D cost amortization as part of the
business case will be misleading. Putting
it the other way round, this principles
claims that R&D expenses have to be paid
out of ”regular actual revenue”. 
The case of marketing expenses: They usu-
ally comprise a major part of a pharmaceu-
tical company's expenses (Consumer Pro-
ject on Technology, 1999). They must not
be allocated to the business cost case for
such kind of programs, as the recipients -
in Pfizer's program – must have been pres-
cribed those drugs prior to entry in the pro-
gram. In this constellation marketing is not
necessary by definition as the marketing
effort relating to this single transaction has
taken place before. Thus marketing expen-
ses are not related to the program's bene-
fit at all and hence should be excluded from
the analysis.
Considering the aforementioned commu-
nications aspects, these paradigms should be
considered upfront and also should be part of
the associated marketing campaign. Critics
will point out pretty soon that the opportuni-
ty cost (based on list prices or let alone on an
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excessive cost base) allocated to the program
are fictional, in particular due to the ”lack of
market” argument.
Other benefits might be considered on the
income part of the business case:
Production volume: The additional turno-
ver resulting from products given away for
free may increase overall turnover and
hence reduce the fixed cost portion of the
cost of goods sold.
Revenue from cost reduction: The overall
benefit will come from ‘paying’ contribu-
tion margins to the production facilities
out of a de facto PR cost reduction.
Reduction of tax burden: The additional
production which is associated with cost
but not associated with revenue may
decrease overall taxable profit. This in turn
will reduce the tax burden. In addition to
this, companies may be – depending on the
respective tax regimen – able to claim furt-
her tax reductions for donations based on
the value of their products given away for
free (which, of course, has to be properly
valued in line with the considerations
above).
Considering both tangible and intangible
elements a positive business case for any such
program is not out of reach.
D. Business enhancement through new
distribution channels – neglected
markets
The second strategy approach mentioned
before aims at serving neglected markets with
existing products. Let us consider the follo-
wing company:
The drug to address a focal disease of a
neglected market is readily available.
The drug could be provided at an affordab-
le price (see constellation in the previous
section).
Despite having products ready our compa-
ny may still be scared off from some country
markets by various reasons:
The political environment may not be sta-
ble enough to justify building a producti-
on facility there, while utilizing a local licen-
see would put the intellectual property at
severe risk.
The delivery requires a highly efficient sup-
ply chain in order to make the price afford-
able; due to the political risk mentioned
before, the efficiency cannot be achieved
due to required security measures.
Distribution channels may not be safe. This
creates a heightened risk of feeding the
grey market in the first world rather than
serving the targeted patients.
As stated in an earlier section, the main
success factor for the business case for a solu-
tion here will not be a matter of quantitative
modeling but rather than that finding an
appropriate operating model which tackles
the aforementioned problems. Economically
speaking, the operating model must allow for
eliminating the risk or shifting risk towards
partners while again ensuring contribution
margin from large volumes and low prices. 
Thus the established and well understood
distribution models for pharmaceutical com-
panies are up for discussion themselves. ‘Thin-
king out of the box’, collaboration with new
partners – new in the meaning that they are
not only new to the company, but new to the
industry in general – will be the key:
This might go as far as using the distribu-
tion channels of first world consumer pro-
duct companies, e.g. the well-known soft
drink manufacturers, for the distribution
of products. The rationale here is that they
need to tackle security issues as well.
Establishing new distribution models even
might involve Big Pharma’s natural ene-
mies – those non-government / not-for-pro-
fit organizations who point to the dark spots
on the industry’s clean records and enga-
ge in the ‘access to medicine’ discussions.
These organizations know the markets and
the issues and therefore may be utilized as
monitoring agency in the process.
This theorem can be extended further: the
key success factor for any new distribution
channels will be - for the moment - the role of
NGOs in general. Establishing a new distribu-
tion model in order to serve neglected mar-
kets is more likely to be successful when sup-
ported by a concerted effort by pharmaceuti-
cal companies, distributor companies, natio-
nal governments as well as agencies and
others. Experience indicates that there is a
high risk of power games between these play-
ers. The NGOs – if not considered as actually
being involved, e.g. as a monitoring agency, in
the actual distribution process – may still be
the missing piece here. They may serve as the
neutral intermediary between the diverging
entities as their primary focus – per definiti-
on – is not profit. Hence, a case can be made
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for collaborating with those NGOs in an orches-
trated way to become active players in the pro-
cess for effective and efficient access to health.
Key success factors for successful business case
modeling
As mentioned above, establishing a busi-
ness case here will need to combine different
elements, partially from the previous secti-
ons:
The business case itself will have to put sig-
nificant weight on a thorough risk assess-
ment.
A pricing model should be / can be defined,
which provides for positive contribution
margins.
The distribution model actually has to be
a ‘new one’. It may include and combine
the whole array of instruments here: dona-
tions, licensing, tiered pricing, sales to insti-
tutional developers, etc.
Any such new distribution model will invol-
ve external partners.
Following the concepts described above
(considering marginal cost of production rat-
her than total cost, focusing on contribution
margin accounting and appropriate conside-
ration of soft factors, including reputational
risk) business cases here still will provide sig-
nificant upside potential.
Similar to the (more obvious) case of
neglected diseases discussed below, a long-
term benefit of this strategy may arise besi-
des this short-term ‘hard fact benefit’. There
is a (although possibly weak) reciprocal link
between serving neglected markets and the
status as a neglected market. The basic assump-
tion of this theory is that serving a market
which is neglected and not served yet becau-
se of its instability will contribute to public
health and to general well being of the respecti-
ve public in the respective country. This in turn
may contribute to stabilizing a formerly insta-
ble market. Thus a neglected market may turn
into a desirable target market giving further
rise to the validity of the business case.
E. Business enhancement through pro-
duct structure – neglected diseases
A major example for a successful program
in the ‘neglected diseases’ domain is Novartis
fight against Malaria. Novartis enforced its
Malaria research, although Malaria is not pre-
valent in Novartis’ primary markets. The cor-
nerstone of this program is providing drugs
at a very low price to very large market.
One goal behind this initiative is clearly
corporate responsibility, as Novartis is highly
aware of the death toll Malaria is still causing
outside the first world. The program, howe-
ver, is a good example for an approach which
goes beyond purely serving a corporate citi-
zenship purpose – such efforts may not neces-
sarily be solely investments without return.
‘Neglected diseases’ can very well be profitab-
le disease targets for companies, as the requi-
red low price may be offset by the enormous
number of patients.
The experience of GlaxoSmithKline proved
the validity of this approach (Financial Times,
2009). According to GSK, price cuts of 30-50%
had volumes increase by 15-40%; the price
reduction of one particular drug yielded a sales
increase by 700%.
Key success factors for successful business case
modeling
The key lever for a business case for such a
program is going away from a total cost of pro-
duct point of view towards a contribution mar-
gin oriented approach. The principle of con-
tribution margin accounting is computing
what a product’s revenue less the cost direct-
ly incurred by producing the product (usual-
ly variable costs) contributes to covering the
fixed cost of operations and administration.
The case of negative contribution margin
shows that the product does not even cover its
direct (variable) cost neither does it contribu-
te to covering the fixed cost of the company.
In practice, this principle is applied by defi-
ning different ‘layers’ of a company to which
costs can be directly allocated. Direct cost of
production can be allocated to a single pro-
duct instance, so that a ‘contribution margin
I’ (CM I) is computed for the product. Overhead
cost of production and sales may be directly
allocated (without using allocation keys) to a
division level, so that a ‘contribution margin
II’ (CM II) is computed for a division by put-
ting the margins of each product of the divi-
sion against the related overhead and so on.
Applying this principle here aims at crea-
ting a positive contribution margin for a par-
ticular product by achieving a volume large
enough so that the (mathematical) product of
price and volume provides at least a positive
contribution margin and – in the best case –
a margin which substantially contributes to
the division’s cost. If such a situation is achie-
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ved, the bottom line impact is positive by defi-
nition.
The pricing decision itself again must not
be based on the total cost of the product. The
aspects of using total cost are ‘covered’ by using
the contribution margin accounting approach
instead.
Besides this short-term ‘hard fact benefit’
a long-term benefit of this strategy may arise,
too. Developing a drug for a third world mar-
ket does not necessarily mean that the drug
will not be used in first world markets. As glo-
bal epidemics in the past (e.g. SARS) have
shown, diseases may spread into first world
markets. Having drugs ready in the cupboard
certainly will ‘help’. The scenario may be con-
sidered as far fetched thought. Globalization,
however, is just one driver for such develop-
ments. Climate change is a fact and will also
give rise to diseases from warmer climate zones
in places where they are not expected now.
These ideas might be given consideration
in the business case at product level, although
the impact will be of qualitative nature only
– it will be nearly impossible to reliably defi-
ne a hard quantitative impact for such a case.
F. Conclusion
Due to its importance and its impact on
personal level ‘access to medicine’ / ‘global
access’ deserves maximum attention by the
pharmaceuticals industry and also needs to
consider new approaches, which to some
extent have to be created ‘out of the box’.
‘Access to medicine’ is oftentimes seen as a
topic which is part of corporate responsibili-
ty and belongs to corporate citizenship in the
model depicted above. Nevertheless, it helps
the case to create ways which allow for ser-
ving the initial purpose – providing access for
those who otherwise would get no medicati-
on – whilst providing economic benefit at the
same time. This will require new coalitions in
an orchestrated approach, but also creativity
in terms of upfront business modeling.
Besides this result, the concepts discussed
above may lead to an additional conclusion.
The different types of response to the ‘access
to medicine’ challenge are a result of corpora-
te responsibility in the first place, but also fit-
ting and shaping economic needs. Thus, the
authors make – independent of the industry
a company is competing in – a case for consi-
dering corporate responsibility as a major
management tool to be used when a compa-
ny is facing adversity.
This theory is supported by evidence from
the current financial and economic crisis: on
the one hand the lack of responsibility of the
financial industry towards non-shareholding
stakeholders was a major driver of the crisis.
On the other hand, using the toolbox, which
is provided by corporate responsibility, com-
panies avoid getting even deeper into trou-
bles (e.g. by financially supporting suppliers
in major financial woes as seen in the auto-
motive industries) or getting out of the cur-
rent situation (e.g. by entering low-profit mar-
kets or markets which just allow for recove-
ring the costs and thereby ensuring the requi-
red utilization of production facilities).
Generally speaking, the corporate respon-
sibility toolbox is a valuable instrument for
shaping the corporate future aligned with its
strategy. This is true for the strategy options
discussed above, for which corporate respon-
sibility can be transformed into a valid busi-
ness case. In particular the theory holds true
for the concept of stabilizing markets through
general health improvement by serving
neglected markets. Any value-based perfor-
mance management instrument, such as eco-
nomic value added (EVA), is incorporating risk
into its formula. Thus stability as the counter-
part to risk is driving economic success. It is,
however, not limited to creating stability in
neglected markets – addressing neglected
diseases may in the long term ensure stabili-
ty in first world markets as they need to be
prepared for new diseases. Globalization and
climate change may pave the diseases’ path
into the first world. Contributing to have one’s
home market be prepared may be one piece
of the EVA puzzle.
Pharma’s corporate responsibility toolbox
in the ‘access to medicine’ domain can provi-
de for another contribution to shaping the
future. Entering areas not served before also
helps understanding a new area and open the
door to a new field for innovation. Biology, for
example, was ‘neglected’ by Big Pharma in the
past – nowadays the biotech revolution can be
considered one of the drivers of the health care
industry. Understanding areas not understood
before hence will be a driver for innovation in
the future. This shall not comprise a case for
patenting natural medicine and natural
healing methods, but for serving neglected
areas – patients, markets and diseases – and
learning from this experience to shape your
own future.
These are examples for the power of corpo-
rate responsibility. For this reason the authors
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expect that the current crisis will strengthen
the need for corporate responsibility across
industries, as value generation from corpora-
te responsibility will be more visible and more
appreciated these days than any time before.
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